A REVOLUTIONARY STENT SYSTEM TO TREAT COMPLEX CORONARY LESIONS

BIODEGRADABLE DRUG ELUTION

Sirolimus-eluting cobalt chromium coronary stent technology.
Unmatched deliverability and XLIMUS performance.

The most innovative Sirolimus-eluting cobalt chromium coronary stent technology available.
XLIMUS is the ultimate coronary DES stent system to treat complex coronary artery disease by reaching and crossing the most challenging lesions.

XLIMUS offers a stable, flexible stent delivery system featuring a flexible tip technology allowing navigating the most tortuous coronary anatomies.

XLIMUS is a next generation thin stent strut Sirolimus DES, using the No. 1 drug which demonstrated long-term patient safety and optimal clinical efficacy, in more than 10.0 Million Patients.
The outstanding XLIMUS 6-8-10 stent cell design.

Ensures even vessel wall coverage. Any different artery lesion diameter ranging from 2.25 up to 5.00mm is stented evenly.
No stent flaring. No open gaps. The technically high standard of 6-8-10 intermediate and closed-cell stent architecture covers all vessel diameters evenly. XLIMUS quality ensures the best possible intracoronary stenting stability and minimizes stenting trauma and restenosis. Extraordinary homogenous vessel wall scaffolding.

XLIMUS assists the cardiologist with an optimal, unsurpassed tracking performance. It has an innovative Hydrophilic-coated shaft and an extra-low tip profile to access the most tortuous lesions. The ultra-low lesion crossing profile measures only 0.90 mm. The novel XLIMUS Sirolimus-eluting coronary stent system protects the stented lesion segment through extraordinary homogeneous vessel wall scaffolding which minimizes the risk of tissue prolapse.

Homogenous, clinically effective drug delivery optimizes the anti-proliferative protection of the stented lesion segment.
XLIMUS drug-coating technology.

A novel drug-eluting, cobalt chromium coronary stent system, which provides clinically effective antiproliferative, drug delivery to the coronary artery lesion to prevent restenosis, followed by a rapid functional endothelial healing.

- Biodegradable Polymer
- Sirolimus Drug Elution

Following the nature. Stent flexibility by design.

Pulse Synchronous Stent Dynamics respond to coronary artery movement, with every heart beat. Natural stent flexion minimizes friction and shear stress to avoid vessel wall trauma. For a lifetime patient safety!

Controlled biodegradable Sirolimus drug release for rapid functional endothelial healing.

The highly biocompatible Poly (lactic acid) drug containing release matrix degrades smoothly and provides an optimal release kinetic profile. Within 30 days, about 70% of the anti-proliferative drug is distributed into the surrounding arterial tissue of the stent struts, ensuring a highly effective inhibition of smooth muscle cell migration and proliferation. Pharmacokinetic study result confirm sustained anti-proliferative drug efficacy up to 120 days.

Thin stent struts minimize foreign body metal volume.

XLIMUS reduces the inflammatory signal potential for prevention of late restenosis.

<table>
<thead>
<tr>
<th>Stent</th>
<th>Thickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cypher</td>
<td>140 μm</td>
</tr>
<tr>
<td>Taxus Liberte</td>
<td>97 μm</td>
</tr>
<tr>
<td>Endeavor</td>
<td>91 μm</td>
</tr>
<tr>
<td>Xience V</td>
<td>81 μm</td>
</tr>
<tr>
<td>XLIMUS*</td>
<td>71 μm</td>
</tr>
</tbody>
</table>

Life deserves the best.

XLIMUS controlled biodegradable Sirolimus drug release.

XLIMUS ensures a controlled drug release after stent implantation.
Technical Data

Material: Cobalt Chromium Alloy L-605

Total strut thickness: 73µm (71µm Alloy + 2µm coating layer)

Coating layer: 2µm

Device lengths: Stent length = balloon length = markers distance

Metal to artery ratio: 14% average

Nominal pressure: 8 ATM

Rated burst pressure: 16 ATM except diameters 4.5 / 5.0 and diameter 4.0 with length higher than 20mm (14 ATM)

Average foreshortening: < 1%

Guiding catheter compatibility: 5F (0.058" ID) except diameters 4.5 and 5.0 —> 6F (0.071")

Guidewire compatibility: 0.014" maximum recommended

Sirolimus (Rapamycin) drug-coating: 1.25µg/mm² stent surface

*upon request, no lead time available